BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30593907)

  • 1. Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Wegener D; Lang P; Paulsen F; Weidner N; Zips D; Ebinger M; Holzer U; Döring M; Basu O; Gruhn B; Wittig A; Teltschik HM; Handgretinger R; Heinzelmann F
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):137-143. PubMed ID: 30593907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation.
    Wegener D; Lang P; Paulsen F; Weidner N; Zips D; Ebinger M; Holzer U; Döring M; Heinzelmann F
    Strahlenther Onkol; 2022 Jan; 198(1):66-72. PubMed ID: 34476532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients.
    Teltschik HM; Heinzelmann F; Gruhn B; Feuchtinger T; Schlegel P; Schumm M; Kremens B; Müller I; Ebinger M; Schwarze CP; Ottinger H; Zips D; Handgretinger R; Lang P
    Br J Haematol; 2016 Oct; 175(1):115-22. PubMed ID: 27341180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
    Chewning JH; Castro-Malaspina H; Jakubowski A; Kernan NA; Papadopoulos EB; Small TN; Heller G; Hsu KC; Perales MA; van den Brink MR; Young JW; Prockop SE; Collins NH; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1313-23. PubMed ID: 17950918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
    J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
    Choe HK; Gergis U; Mayer SA; Nagar H; Phillips AA; Shore TB; Smith MJ; van Besien K
    Transplantation; 2017 Jan; 101(1):e34-e38. PubMed ID: 27764032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen.
    Wang SB; Li L; Pan XH; Hu DM; Peng LH; Liu L; Xie ZJ; Yin B; Sun XJ; Yu J; Liang Y
    Clin Transplant; 2013; 27(2):E109-15. PubMed ID: 23387380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
    Madden LM; Hayashi RJ; Chan KW; Pulsipher MA; Douglas D; Hale GA; Chaudhury S; Haut P; Kasow KA; Gilman AL; Murray LM; Shenoy S
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1467-1472. PubMed ID: 27164064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients.
    Lang P; Mueller I; Greil J; Bader P; Schumm M; Pfeiffer M; Hoelle W; Klingebiel T; Heinzelmann F; Belka C; Schlegel PG; Kremens B; Woessmann W; Handgretinger R
    Blood Cells Mol Dis; 2008; 40(1):33-9. PubMed ID: 17884640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.